Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has contracted Atheln Inc. (" Atheln "), a leading US consulting firm, to bolster and facilitate Sirona's business activities. This strategic initiative comes at an opportune time, as Sirona prepares for the highly anticipated BIO International 2023 conference in Boston, where it will showcase its groundbreaking anti-aging compound, TFC-1326 . Under the guidance of Monica Alfaro Welling Atheln will spearhead the project team to ensure the success of Sirona's meetings during the conference.

The primary focus of the contract is to meticulously prepare for the BIO International conference, where Sirona aims to establish valuable partnerships for the development and commercialization of TFC-1326. Recognizing the significance of these meetings, the collaboration with Atheln aims to maximize the probability of success. Sirona's team has secured numerous meetings with organizations and companies that possess complementary resources, capabilities, and a strategic interest in partnerships.

Sirona recognizes that effective communication, thorough preparation, and a clear value proposition significantly enhance the likelihood of finding suitable partners for TFC-1326 at the BIO International conference.

Following the conclusion of the BIO conference, Sirona will continue to work with Atheln to extend its global outreach to companies that did not attend the event. By expanding efforts to establish valuable connections and collaborations, Sirona aims to forge strategic alliances and broaden the reach of its innovative solutions.

About Monica Alfaro Welling, MBA – Commercial/Business Development

With over 30 years of experience in new product planning, strategic planning, portfolio analysis, market development and sales/marketing, business development of pharmaceuticals, biotechnology, and medical devices, Monica has had a unique career in the life science industry. She has been involved in every aspect of the development and commercialization process of early and late-stage technologies and new therapeutic applications. Monica has launched several disruptive technologies including BOTOXand been involved in a number of programs targeting the aesthetic market. Throughout her career, she has led development of commercial strategies including positioning, messaging, KOL development, reimbursement strategies and clinical studies to support positioning. In addition, her experience spans across a multitude of therapeutic areas including dermatology (clinical and aesthetics), oncology, ophthalmology, endocrinology, CNS, pain, addiction, back pain, and orphan diseases. Through her C-suite experience and consulting, Monica has been involved in fundraising (public and private) and licensing activities including profiling of potential strategics, outreach and defining deal terms. Prior to her consulting career, she held executive and management roles at Allergan, Novo Nordisk, and a start-up company. She has an MBA from Southern Danish University in Denmark, as well as a BS in Biology and a BA in Economics from the University of California, Irvine.

About Atheln, Inc.

Atheln helps clients create and execute integrated pharma and biotech product development and commercialization strategies. With a global team of over 100 highly specialized, industry-seasoned experts Atheln's team excel at risk identification and mitigation, while delivering phase appropriate and customized solutions that maximize value and increase the likelihood of success for our clients. For more information, please visit www.athelnbiomed.com .

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located an hour north of Paris, France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

BOTOX COSMETIC® is a registered trademark of Allergan, Inc.

For more information regarding this press release, please contact:
Investor Enquiries:
Email: Info@sironabiochem.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SBM:CA
Sirona Biochem

Sirona Biochem Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
GlycoProteMim Featured in Stonegate Healthcare's Latest Anti-Aging Research Report

GlycoProteMim Featured in Stonegate Healthcare's Latest Anti-Aging Research Report

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare's newly published research report, "Novel Treatments for Age-Related Skin Problems." The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.

The research highlights GlycoProteMim alongside other prominent active ingredients such as OneSkin's OS-01, Sisley Paris' Soy Peptides, SK-II's Pitera™, and SkinMedica's TNS Advanced Serum. GlycoProteMim is recognized for its unique approach to skin rejuvenation, addressing both surface-level appearance and underlying cellular mechanisms, making it a standout in the evolving landscape of skincare treatments.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Stonegate Healthcare Partners Announces Publication of Thematic Report on Anti-Aging Dermatology Innovations

Stonegate Healthcare Partners Announces Publication of Thematic Report on Anti-Aging Dermatology Innovations

Stonegate Healthcare Partners, a leading name in healthcare consultancy and market intelligence, is pleased to announce the publication of a comprehensive thematic report titled "Leading Innovations in Anti-Aging Dermatology." This report delves into the transformative advancements in the treatment of age-related skin conditions, focusing on cutting-edge technologies and personalized holistic approaches that are poised to revolutionize the skincare industry.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Emerging novel topicals: Innovations like OneSkin's OS-01, Sirona Biochem's GlycoProteMim, and SK-II's Pitera offer signficant benefits that will let them take market share away from existing treatments.
  • Personalized and holistic skincare: Advances ingenomics, skin diagnostics, and AI-driven tools enable tailored treatment plans ushering in a new era of skincare.
  • Companies highlighted in this report are: SkinMedica, SK-II, Sirona Biochem (TSXV: SBM), One Skin, and CTEK Sisley.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/213432_figure1_550.jpg

Click image above to view full announcement.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate's extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona's anti-aging ingredient, GlycoProteMimTM, to effectively assess and demonstrate its market potential within the global anti-aging skincare industry.

About Sirona Biochem Corp.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Elixinol Wellness Limited

Strategic Acquisition and Capital Raising - Investor Presentation | 3 October 2024

Elixinol Wellness Ltd. (”EXL”) has entered into a binding agreement to acquire 100% of the business assets from the entities ("Acquisition") that together form The Healthy Chef business ("Healthy Chef").

Keep reading...Show less
Radiopharm Theranostics

Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce regulatory and manufacturing progress for its B7-H3 targeting radio-antibody, BetaBart.

Keep reading...Show less
Hydralyte

Completion of Divesture of Non-US Assets

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte US” or “the Company”) refers to its announcement released pre-open on 2 October 2024 regarding entry into an Intellectual Property Sales Agreement (the ‘Agreement’) and related documents with Prestige Consumer Healthcare Inc. and associated subsidiaries.

Keep reading...Show less
Hydralyte

Divesture of Non-US Assets for ~US$9.5M (~A$13.7M) Allowing for Payoff of A$8.2M Debt Facility while Funding Expansion of US Business

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to announce that it has entered into an Intellectual Property Sales Agreement (the ‘Agreement’) with Prestige Consumer Healthcare Inc. and associated subsidiaries (together, ‘Prestige’). Pursuant to the Agreement and associated arrangements, the Company will assign and transfer the exclusive right to sell Hydralyte products, and associated intellectual property rights, to Prestige in all relevant jurisdictions other than the United States of America.1

Keep reading...Show less

LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE

Campaign Encourages Open Dialogue With Doctor About Unmanaged Symptoms to Find the Right Treatment Option

Amgen (NASDAQ: AMGN) has partnered with multi-talented actress, producer and entrepreneur La La Anthony to share her personal journey living with plaque psoriasis, and to inspire people to be open with their doctors about how the disease affects their daily lives. As one of the more than 6 million people in the United States living with plaque psoriasis, La La understands the frustrations of living with this disease. Symptoms can distract from everyday moments, big and small, even influencing clothing or makeup choices. 1,2

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Announces Publication of Breakthrough Study Validating Noninvasive Fingertip Photoplethysmography  for Central Aortic Pressure Waveform Analysis

Cardiex Announces Publication of Breakthrough Study Validating Noninvasive Fingertip Photoplethysmography for Central Aortic Pressure Waveform Analysis

Cardiex Limited (ASX: CDX), a global health technology company focused on cardiovascular diagnostics and arterial health solutions, today announced the publication of a peer-reviewed study validating its innovative method for measuring central aortic pressure—an important indicator of heart health—using a noninvasive fingertip sensor. The study, co-authored by Cardiex's team, was published in the respected journal Pulse.

Cardiex logo (PRNewsfoto/CardieX Limited)

The study, titled "Validation of Noninvasive Derivation of the Central Aortic Pressure Waveform from Fingertip Photoplethysmography Using a Novel Selective Transfer Function Method," demonstrates that Cardiex's technology can accurately capture key cardiovascular data from a simple fingertip sensor. The method leverages photoplethysmography (PPG)—an optical technique widely used in wearables such as fitness trackers and smartwatches—offering a powerful and accessible tool for advanced heart health monitoring.

Key findings include:

  • Strong correlation between fingertip sensor measurements and traditional methods, with heart health indicators showing excellent alignment.
  • The fingertip sensor offers a user-friendly, noninvasive way to measure central aortic pressure parameters without calibration, making heart health monitoring more accessible and comfortable.
  • Twenty clinically relevant parameters were captured from the converted PPG waveforms, including central systolic blood pressure, central diastolic blood pressure, central pulse pressure, central augmentation pressure, central augmentation index, subendocardial viability, and pulse pressure amplification, amongst others.

Relevance in the Wearable Health Market:

The use of PPG technology in this study is especially significant as the wearable market continues to expand, with consumers seeking more advanced health insights without the need for frequent calibration. Cardiex's innovation aligns with this trend offering consumers the ability to track clinical grade biomarkers in real-time. These biomarkers have applications in various healthcare fields, including cognitive, renal, maternal, metabolic health, and heart failure management. The technology's ease of use and capacity for continuous monitoring place Cardiex at the forefront of the growing wearable health sector, which increasingly prioritizes deeper and more accurate health data.

"This study is a significant validation of Cardiex's technology and its ability to deliver critical heart health insights in a simpler, more convenient way," said Craig Cooper , CEO of Cardiex. "Our PPG-based fingertip technology has the potential to transform heart health monitoring, offering a more accessible option for both patients and healthcare providers. This breakthrough also opens up exciting opportunities for integration into the wearable health tech market, where continuous and noninvasive monitoring is becoming the gold standard."

The study confirms that Cardiex's PPG-based solution can provide valuable cardiovascular data in a comfortable, portable format, paving the way for broader adoption in both medical and consumer-grade wearables.

The full study is now available online in the journal Pulse DOI: 10.1159/000540666.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/cardiex-announces-publication-of-breakthrough-study-validating-noninvasive-fingertip-photoplethysmography-ppg-for-central-aortic-pressure-waveform-analysis-302259185.html

SOURCE Cardiex Limited

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem

Sirona Biochem Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×